Skip to main content
Top
Published in: BMC Psychiatry 1/2018

Open Access 01-12-2018 | Research article

First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort

Authors: Nobuhisa Kanahara, Hiroshi Yamanaka, Tomotaka Suzuki, Masayuki Takase, Masaomi Iyo

Published in: BMC Psychiatry | Issue 1/2018

Login to get access

Abstract

Background

Approximately one-third of schizophrenia patients eventually develop treatment-resistant schizophrenia (TRS). Although the time course of TRS development varies from patient to patient, the details of these variations have not been clarified. The present study compared the duration of time required to achieve control of the first-episode psychosis (FEP) between patients who went on to develop TRS and those who did not, in order to determine whether a bifurcation point exists for the transition to TRS.

Methods

The present study included 271 schizophrenia patients. Based on the clinical assessment, each patient was assigned to a TRS (n = 79) or Non-TRS group (n = 182). Clinical factors relating to FEP treatment such as the duration of initial hospital admission and the degree of improvement were retrospectively identified.

Results

There was no significant difference in the duration of initial hospital admission (defined as the time from treatment introduction to successful discharge) between the two groups (mean of 87.9 days for TRS vs. 53.3 days for Non-TRS). The degree of improvement during initial hospital admission of the TRS group was significantly lower than that of the Non-TRS group (Global Assessment of Functioning (GAF) of 50 points for TRS vs. 61 points for Non-TRS). Approximately half of the TRS patients showed an acute onset pattern and longer hospital admission (mean 169 days) for their FEP. The other half of TRS patients needed no hospital admission, indicating an insidious onset pattern with no clear psychotic episode and treatment introduction without hospital admission.

Conclusions

Future TRS patients can have difficulty in improvement during their FEP. There appear to be two distinct patterns for the development of TRS. One pattern is characterized by refractory positive symptoms and a longer period to control the first psychosis; the other shows latent or insidious onset and poor response to the initial treatment.
Literature
1.
go back to reference Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 2008;102:1–18.CrossRefPubMed Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 2008;102:1–18.CrossRefPubMed
2.
go back to reference Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trails with a retrospective data analysis. J Clin Psychiatry. 2011;72:1439–44.CrossRefPubMed Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trails with a retrospective data analysis. J Clin Psychiatry. 2011;72:1439–44.CrossRefPubMed
3.
go back to reference Chiliza B, Asmal L, Lilian S, Phahladira L, Emsley R. Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia. Hum Psychopharmacol Clin Exp. 2015;30:173–82.CrossRef Chiliza B, Asmal L, Lilian S, Phahladira L, Emsley R. Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia. Hum Psychopharmacol Clin Exp. 2015;30:173–82.CrossRef
4.
go back to reference Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544–5491.CrossRefPubMed Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544–5491.CrossRefPubMed
5.
go back to reference Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv. 1995;46:801–6.CrossRefPubMed Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv. 1995;46:801–6.CrossRefPubMed
6.
go back to reference Kane J, Honigfeld G, Singer J, Melzer H. The Clozaril collaborative study group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.CrossRefPubMed Kane J, Honigfeld G, Singer J, Melzer H. The Clozaril collaborative study group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.CrossRefPubMed
7.
go back to reference Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, Mondelli V, Marques TR, Pariante C, Dazzan P, Shergil SS, Howes O, David AS, MacCabe JH, Gaughran F, Murray RM. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231–40.CrossRefPubMed Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, Mondelli V, Marques TR, Pariante C, Dazzan P, Shergil SS, Howes O, David AS, MacCabe JH, Gaughran F, Murray RM. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231–40.CrossRefPubMed
8.
go back to reference Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, Heslin M, Reininghaus UA, Donoghue K, Lomas B, Charalambides M, Onyejiaka A, Fearon P, Jones P, Doody G, Morgan C, Dazzan P, Murray RM. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47:1981–9.CrossRefPubMed Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, Heslin M, Reininghaus UA, Donoghue K, Lomas B, Charalambides M, Onyejiaka A, Fearon P, Jones P, Doody G, Morgan C, Dazzan P, Murray RM. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47:1981–9.CrossRefPubMed
9.
go back to reference Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatr Research. 2015;227:278–82.CrossRef Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatr Research. 2015;227:278–82.CrossRef
10.
go back to reference Yamanaka H, Kanahara N, Suzuki T, Takase M, Moriyama T, Watanabe H, Hirata T, Asano M, Iyo M. Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: an analysis of multi-factors predicting long-term prognosis. Schizophr Research. 2016;170:252–8.CrossRef Yamanaka H, Kanahara N, Suzuki T, Takase M, Moriyama T, Watanabe H, Hirata T, Asano M, Iyo M. Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: an analysis of multi-factors predicting long-term prognosis. Schizophr Research. 2016;170:252–8.CrossRef
11.
go back to reference Harrison G, Croudace T, Mason P, Glazebrook C, Medley I. Predicting long-term outcome in schizophrenia. Psychol Med. 1996;26:697–705.CrossRefPubMed Harrison G, Croudace T, Mason P, Glazebrook C, Medley I. Predicting long-term outcome in schizophrenia. Psychol Med. 1996;26:697–705.CrossRefPubMed
12.
go back to reference Morgan C, Abdul-Al R, Lappin JM, Jones P, Fearon P, Leese M, Croudace T, Morgan K, Dazzan P, Craig T, Leff J, Murray R. Clinical and social determinants of duration of untreated psychosis in the ÆSOP first-episode psychosis study. Br J Psychiatry. 2006;189:446–52.CrossRefPubMed Morgan C, Abdul-Al R, Lappin JM, Jones P, Fearon P, Leese M, Croudace T, Morgan K, Dazzan P, Craig T, Leff J, Murray R. Clinical and social determinants of duration of untreated psychosis in the ÆSOP first-episode psychosis study. Br J Psychiatry. 2006;189:446–52.CrossRefPubMed
13.
go back to reference Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, Fervaha G, Remington G. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol. 2013;23:1017–22.CrossRefPubMed Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, Fervaha G, Remington G. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol. 2013;23:1017–22.CrossRefPubMed
14.
go back to reference Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160:2063–5.CrossRefPubMed Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160:2063–5.CrossRefPubMed
15.
go back to reference Leuchit S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68:352–60.CrossRef Leuchit S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68:352–60.CrossRef
16.
go back to reference Schennach-Wolff R, Seemüller FH, Mayr A, Klingberg MS, Klosterkötter J, Gastpar M, Häfner H, Sauer H, Schneider F, Gaebel W, Jäger M, Möller HJ, Riedel M. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry. 2010;196:460–6.CrossRefPubMed Schennach-Wolff R, Seemüller FH, Mayr A, Klingberg MS, Klosterkötter J, Gastpar M, Häfner H, Sauer H, Schneider F, Gaebel W, Jäger M, Möller HJ, Riedel M. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry. 2010;196:460–6.CrossRefPubMed
17.
go back to reference Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry. 1996;153:519–25.CrossRefPubMed Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry. 1996;153:519–25.CrossRefPubMed
Metadata
Title
First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort
Authors
Nobuhisa Kanahara
Hiroshi Yamanaka
Tomotaka Suzuki
Masayuki Takase
Masaomi Iyo
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2018
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-018-1853-1

Other articles of this Issue 1/2018

BMC Psychiatry 1/2018 Go to the issue